SANA Stock Overview
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Sana Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.48 |
| 52 Week High | US$9.60 |
| 52 Week Low | US$3.15 |
| Beta | 0.60 |
| 1 Month Change | 14.29% |
| 3 Month Change | -25.58% |
| 1 Year Change | -39.21% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -87.24% |
Recent News & Updates
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Dec 19
Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 03Recent updates
We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Dec 19Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 03Sana Biotechnology A Buy For Potential Cancer Therapies
Jun 27Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
May 16Sana Biotechnology: Exciting Preclinical Science
Feb 12Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?
Oct 13Sana Biotechnology: Hypoimmune Cell Therapies
Jul 01Sana Biotechnology reports Q1 results
May 05Shareholder Returns
| SANA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.9% | -1.8% | -1.8% |
| 1Y | -39.2% | 1.9% | -10.9% |
Return vs Industry: SANA underperformed the US Biotechs industry which returned 1.9% over the past year.
Return vs Market: SANA underperformed the US Market which returned -10.9% over the past year.
Price Volatility
| SANA volatility | |
|---|---|
| SANA Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SANA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: SANA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 497 | Steve Harr | https://www.sana.com |
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency.
Sana Biotechnology, Inc. Fundamentals Summary
| SANA fundamental statistics | |
|---|---|
| Market Cap | US$850.84m |
| Earnings (TTM) | -US$299.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs SANA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$299.76m |
| Earnings | -US$299.76m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.58 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SANA perform over the long term?
See historical performance and comparison